Literature DB >> 22819787

Effect of autoimmune diseases on risk and survival in female cancers.

Kari Hemminki1, Xiangdong Liu, Jianguang Ji, Asta Försti, Jan Sundquist, Kristina Sundquist.   

Abstract

OBJECTIVES: Patients with autoimmune (AI) diseases are diagnosed with increased frequencies of some cancers, which may depend on the underlying dysregulation of the immune system or treatment. Data on female cancers are limited.
METHODS: We analyzed systematically risk and survival of female cancers of the breast, uterus, ovary and other genital organs in close to 200,000 patients diagnosed with any of 33 different AI diseases. Standardized incidence ratios (SIRs) for risk and hazard ratios (HRs) for survival were calculated for subsequent incident cancers or cancer deaths up to year 2008.
RESULTS: For all breast cancer after any AI diseases, the SIR was 0.94; SIRs were modestly increased after two AI diseases and decreased after nine AI diseases, including Sjogren syndrome (0.46). For cervical cancer, the risk was increased after discoid lupus erythematosus (3.34) and systemic sclerosis (2.43). The HR was 2.12 in chronic rheumatic heart disease patients. The overall SIR for endometrial cancer was 0.85, with low SIR in ankylosing spondylitis (0.37); the HR was 4.05 for Sjogren syndrome. The SIR for ovarian cancer was increased for polymyositis/dermatomyositis (3.26) while the HR was increased for multiple sclerosis (2.43). The overall SIR for other genital cancers was increased to 1.54 and a very high risk of 35.88 was observed in localized scleroderma.
CONCLUSIONS: Breast, endometrial and ovarian cancers were decreased after all AI diseases and most significant changes after individual AI diseases were towards lower risks. Probably treatment related factors explain the findings. For cervical and other genital cancers all significant changes were increased risks.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22819787     DOI: 10.1016/j.ygyno.2012.07.100

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  27 in total

1.  E2/Estrogen receptor/sjogren syndrome-associated autoantigen relieves coactivator activator-induced G1/S arrest to promote breast tumorigenicity.

Authors:  Yun Kyoung Kang; Sung Yun Jung; Jun Qin; Chao Li; Sophia Y Tsai; Ming-Jer Tsai; Bert W O'Malley
Journal:  Mol Cell Biol       Date:  2014-02-24       Impact factor: 4.272

2.  Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.

Authors:  Catherine Schairer; Ruth M Pfeiffer; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2017-11-24       Impact factor: 7.396

Review 3.  A review on SLE and malignancy.

Authors:  May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-10       Impact factor: 4.098

4.  Ankylosing spondylitis and the risk of cancer.

Authors:  Chih-Cheng Chang; Cheng-Wei Chang; Phung-Anh Alex Nguyen; Tzu-Hao Chang; Ya-Ling Shih; Wen-Ying Chang; Jorng-Tzong Horng; Oscar Kuang-Sheng Lee; Jennifer Hui-Chun Ho
Journal:  Oncol Lett       Date:  2017-06-09       Impact factor: 2.967

5.  Cervical neoplasia in systemic lupus erythematosus: a nationwide study.

Authors:  Hjalmar Wadström; Elizabeth V Arkema; Christopher Sjöwall; Johan Askling; Julia F Simard
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

6.  Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.

Authors:  Yi Yu-Rice; Seby L Edassery; Nicole Urban; Ingegerd Hellstrom; Karl Erik Hellstrom; Youping Deng; Yan Li; Judith L Luborsky
Journal:  Reproduction       Date:  2016-12-13       Impact factor: 3.906

Review 7.  [Gynecological cancers in patients with inflammatory rheumatic diseases].

Authors:  M Schmalzing; M Krockenberger; A Honig; H-P Tony
Journal:  Z Rheumatol       Date:  2016-02       Impact factor: 1.372

8.  Glucocorticoid prescriptions and breast cancer recurrence: a Danish nationwide prospective cohort study.

Authors:  L W Lietzen; T Ahern; P Christiansen; A B Jensen; H T Sørensen; T L Lash; D P Cronin-Fenton
Journal:  Ann Oncol       Date:  2014-09-15       Impact factor: 32.976

9.  The Prevalence of Systemic Rheumatic Diseases Among Breast Cancer Patients and Its Relationship With Survival.

Authors:  Veli Sunar; Öztürk Ateş; Alma Korcali Aslan; Yusuf Karakaş; Mustafa Kadri Altundağ
Journal:  Arch Rheumatol       Date:  2018-08-16       Impact factor: 1.472

10.  Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer.

Authors:  Rickard Einefors; Ulrika Kogler; Carolina Ellberg; Håkan Olsson
Journal:  Springerplus       Date:  2013-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.